Legal Representation
Attorney
Kim R. Pearson
USPTO Deadlines
Application History
35 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 13, 2018 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Aug 13, 2018 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Jan 5, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 5, 2018 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jan 5, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 28, 2017 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN | Loading... |
| Aug 1, 2017 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
| Jul 20, 2017 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Jul 19, 2017 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jul 19, 2017 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 19, 2017 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 19, 2017 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jul 19, 2017 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jul 19, 2017 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jul 19, 2017 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jul 19, 2017 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 23, 2017 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| May 15, 2017 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| May 15, 2017 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| May 15, 2017 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Apr 29, 2017 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 28, 2017 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Apr 28, 2017 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 11, 2017 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 11, 2017 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 11, 2017 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 31, 2017 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 30, 2017 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 30, 2017 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 21, 2017 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 21, 2017 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 21, 2017 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 21, 2017 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 18, 2016 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 17, 2016 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Dietary supplements; nutritional supplements; medical foods, namely, medical food supplements and dietetic food supplements, both containing short-chain fatty acids in single molecule form with a release agent that enhances solubility and absorption; nutritional ingredients, namely, a blend of nutrients, namely, short-chain fatty acids in single molecule form with a release agent that ensures solubility and absorption, that are an integral component of medicals foods, for short-chain fatty acid deficiencies in individuals with Autism Spectrum Disorder; nutraceuticals for use as dietary supplements and nutritional supplements; vitamin preparations and mineral preparations to mitigate short-chain fatty acid microbiome deficiencies in individuals with Autism Spectrum Disorder; dietary supplements for restoring health in individuals with diseases, disorders, nutritional deficiencies, and adverse health conditions; therapeutic agents for human medical, medicinal, and therapeutic purposes, namely, increasing butyric acid in the gastrointestinal tract; functional nutrients containing butyric acid and acetic acid to mitigate short-chain fatty acid gut microbiome deficiencies in individuals with Autism Spectrum Disorder; pharmaceutical preparations to mitigate short-chain fatty acid gut microbiome deficiencies in individuals with Autism Spectrum Disorder; specialty nutraceuticals for the dietary management of diseases, disorders, and nutritional deficiencies, namely, short-chain fatty acid gut microbiome deficiencies in individuals with Autism Spectrum Disorder and deficiencies of butyrate in the gastrointestinal tract
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005